FDA denies expanded approval for Alnylam RNA drug

FDA denies expanded approval for Alnylam RNA drug

Submitted by admin on October 9, 2023 - 10:15am
Source: 
BioPharma Dive
News Tags: 
Alnylam
FDA
RNA
Patisiran
ATTR amyloidosis
Headline: 
FDA denies expanded approval for Alnylam RNA drug
snippet: 

The agency rejected Alnylam’s application for approval of its medicine patisiran in people with a rare heart condition, setting back the company’s plans.

Do Not Allow Advertisers to Use My Personal information